Review shows small benefit, significant safety concerns for flibanserin
A meta-analysis of eight clinical trials of the newly approved female hypoactive sexual disorder drug flibanserin show the drug yields minimal benefit, while increasing the risk of dizziness,...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Clinical Trials | Endocrinology